Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:46:07 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Q:BMRN - BIOMARIN PHARMACEUTICAL - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMRN - Q0.257.94·57.982.757.96+1.412.51,417.980,57512,38357.41  57.9624  56.8566.275  49.259214:28:01May 2015 min RT 2¢

Recent Trades - Last 10 of 12383
Time ETExPriceChangeVolume
14:28:09Q57.961.413
14:28:08Q57.951.4010
14:28:01Q57.94671.39671
14:27:58Q57.89591.3459100
14:27:56Q57.92211.3721100
14:27:54Q57.961.413
14:27:34Q57.89481.344848
14:27:19Q57.89221.3422100
14:27:16Q57.961.41100
14:27:12Q57.981.435

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-20 16:20U:BMRNNews ReleaseBioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO(TM) (vosoritide) in Children with Hypochondroplasia
2026-05-18 09:05U:BMRNNews ReleaseBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-04 16:05U:BMRNNews ReleaseBioMarin Reports First Quarter 2026 Financial and Operating Results
2026-05-02 15:30U:BMRNNews ReleaseBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO(TM) (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
2026-04-27 08:44U:BMRNNews ReleaseBioMarin Completes Acquisition of Amicus Therapeutics
2026-04-27 07:30U:BMRNNews ReleaseBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
2026-04-21 16:23U:BMRNNews ReleaseBioMarin Announces Board Leadership Transition
2026-03-12 09:05U:BMRNNews ReleaseBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO(TM) (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetic
2026-02-27 20:00U:BMRNNews ReleaseU.S. Food and Drug Administration Approves BioMarin's PALYNZIQ(TM) (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
2026-02-24 09:00U:BMRNNews ReleaseBioMarin to Participate in Four Upcoming Investor Conferences in March
2026-02-23 16:05U:BMRNNews ReleaseBioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
2026-02-17 09:00U:BMRNNews ReleaseBioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
2026-02-12 16:05U:BMRNNews ReleaseBioMarin Announces Closing of Private Offering of Senior Notes
2026-01-29 16:05U:BMRNNews ReleaseBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
2026-01-26 07:45U:BMRNNews ReleaseBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
2026-01-12 16:05U:BMRNNews ReleaseBioMarin Appoints Arpit Dave Chief Digital and Information Officer
2026-01-08 16:05U:BMRNNews ReleaseBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
2026-01-08 08:30U:BMRNNews ReleaseVeeva and BioMarin Form Long-Term Strategic Partnership
2025-12-19 07:45U:BMRNNews ReleaseBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
2025-11-11 09:00U:BMRNNews ReleaseBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England